China Medicine Corporation (CHME)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
+0.0001 (100.00%)
At close: May 30, 2025
China Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | 2003 - 2004 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '10 Sep 30, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | Dec '07 Dec 31, 2007 | Dec '06 Dec 31, 2006 | Dec '05 Dec 31, 2005 | 2003 - 2004 |
| Revenue | 65.76 | 64.75 | 53.65 | 42.11 | 23.99 | 14.93 | Upgrade
|
| Revenue Growth (YoY) | -4.34% | 20.70% | 27.41% | 75.50% | 60.74% | 43.51% | Upgrade
|
| Cost of Revenue | 43.75 | 45.77 | 38.07 | 29.71 | 15.02 | 8.66 | Upgrade
|
| Gross Profit | 22 | 18.98 | 15.57 | 12.4 | 8.97 | 6.27 | Upgrade
|
| Selling, General & Admin | 8.01 | 5.26 | 3.65 | 3.33 | 1.57 | 0.51 | Upgrade
|
| Research & Development | 2.29 | 1.45 | 0.99 | 0.65 | 0.29 | 0.48 | Upgrade
|
| Operating Expenses | 10.3 | 6.72 | 4.65 | 3.98 | 1.86 | 0.99 | Upgrade
|
| Operating Income | 11.71 | 12.27 | 10.93 | 8.41 | 7.12 | 5.28 | Upgrade
|
| Interest & Investment Income | 0.09 | - | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.08 | 0.09 | 0.02 | -0.2 | 0.41 | Upgrade
|
| EBT Excluding Unusual Items | 11.56 | 12.18 | 11.01 | 8.43 | 6.92 | 5.69 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.93 | - | Upgrade
|
| Other Unusual Items | -2.07 | -7.23 | - | - | - | - | Upgrade
|
| Pretax Income | 9.48 | 4.95 | 11.01 | 8.43 | 5.98 | 5.69 | Upgrade
|
| Income Tax Expense | 3.76 | 3.55 | 2.01 | 1.65 | 1.23 | - | Upgrade
|
| Earnings From Continuing Operations | 5.72 | 1.4 | 9.01 | 6.78 | 4.75 | 5.69 | Upgrade
|
| Minority Interest in Earnings | 0.31 | 0.32 | 0.12 | 0.09 | 0.03 | - | Upgrade
|
| Net Income | 6.03 | 1.72 | 9.13 | 6.88 | 4.79 | 5.69 | Upgrade
|
| Net Income to Common | -0.11 | 1.72 | 9.13 | 6.88 | 4.79 | 5.69 | Upgrade
|
| Net Income Growth | -17.72% | -81.18% | 32.73% | 43.60% | -15.86% | 93.57% | Upgrade
|
| Shares Outstanding (Basic) | 32 | 15 | 15 | 12 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 15 | 15 | 14 | 8 | 7 | Upgrade
|
| Shares Change (YoY) | 107.86% | 0.67% | 12.08% | 78.45% | 17.21% | - | Upgrade
|
| EPS (Basic) | -0.00 | 0.11 | 0.60 | 0.56 | 0.65 | 0.87 | Upgrade
|
| EPS (Diluted) | -0.01 | 0.11 | 0.60 | 0.50 | 0.63 | 0.87 | Upgrade
|
| EPS Growth | - | -81.67% | 20.00% | -20.64% | -27.59% | 93.26% | Upgrade
|
| Free Cash Flow | 6.43 | 13.52 | 1.54 | -2.7 | -3.04 | 1.01 | Upgrade
|
| Free Cash Flow Per Share | 0.20 | 0.88 | 0.10 | -0.20 | -0.40 | 0.15 | Upgrade
|
| Gross Margin | 33.46% | 29.32% | 29.03% | 29.44% | 37.41% | 42.00% | Upgrade
|
| Operating Margin | 17.80% | 18.94% | 20.37% | 19.98% | 29.66% | 35.37% | Upgrade
|
| Profit Margin | -0.17% | 2.65% | 17.01% | 16.33% | 19.96% | 38.12% | Upgrade
|
| Free Cash Flow Margin | 9.78% | 20.88% | 2.88% | -6.41% | -12.69% | 6.74% | Upgrade
|
| EBITDA | 13.41 | 13.28 | 11.35 | 8.72 | 7.28 | 5.38 | Upgrade
|
| EBITDA Margin | 20.39% | 20.51% | 21.15% | 20.71% | 30.33% | 36.07% | Upgrade
|
| D&A For EBITDA | 1.7 | 1.01 | 0.42 | 0.3 | 0.16 | 0.1 | Upgrade
|
| EBIT | 11.71 | 12.27 | 10.93 | 8.41 | 7.12 | 5.28 | Upgrade
|
| EBIT Margin | 17.80% | 18.94% | 20.37% | 19.98% | 29.66% | 35.37% | Upgrade
|
| Effective Tax Rate | 39.66% | 71.68% | 18.21% | 19.56% | 20.55% | - | Upgrade
|
| Revenue as Reported | 65.76 | 64.75 | 53.65 | 42.11 | 23.99 | 14.93 | Upgrade
|
| Advertising Expenses | - | 0.56 | 0.54 | 0.41 | 0.07 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.